Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sea-blue histiocytosis and thrombocytopenia successfully treated with an mTORC1 inhibitor: a case report.

Annals of hematology·2026

Same author

Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report.

Translational lung cancer research·2026

Same author

Genetic variants of thioredoxin interacting protein gene and their association with diabetic peripheral neuropathy in type 2 diabetes mellitus.

Gene·2026

Same author

Nutritional and Flavor Improvement of Enzymatic Hydrolysis in Liquefied-Saccharified Foxtail Millet Syrup: Differences Between Drought-Resistant and High-Yield Hybrid Cultivars.

Journal of food science·2026

Same author

Corrigendum to "Taraxasterol prevents cisplatin-induced cochlear hair cell loss via inducing GNAQ" [Biochem. Pharmacol. 250(Part 1) (2026) 117964].

Biochemical pharmacology·2026

Same author

Superior efficacy of CsA plus ATG over CsA monotherapy in pediatric transfusion-independent moderate aplastic anemia.

Pediatric research·2026

Search research articles

Related Experiment Video

Updated: Jun 18, 2025

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.

Andrew A Bolinger¹, Jun Li¹, Xuping Xie^2,3

¹Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA.

Expert Opinion on Drug Discovery

|July 30, 2024

Summary

Developing broad-spectrum antiviral drugs is crucial for combating highly pathogenic coronaviruses (CoVs) like SARS-CoV, MERS-CoV, and SARS-CoV-2. This approach enhances public health resilience against future viral threats.

Keywords:

Antiviral MERS-CoV SARS-CoV SARS-CoV-2 broad-spectrum coronavirus pandemic post-acute sequelae of SARS-CoV-2 infection

More Related Videos

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Related Experiment Videos

Last Updated: Jun 18, 2025

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Area of Science:

Virology
Infectious Diseases
Drug Discovery

Background:

Highly pathogenic coronaviruses (CoVs) have caused significant global health crises, including the COVID-19 pandemic.
These viruses manifest in diverse clinical presentations, from asymptomatic cases to severe acute respiratory distress syndrome (ARDS), leading to high mortality.

Purpose of the Study:

To discuss strategies for developing broad-spectrum antiviral drugs against coronaviruses.
To highlight lessons learned from recent pandemic-driven advancements in antiviral research.

Main Methods:

Review of strategies targeting viral non-structural and structural proteins.
Exploration of drug repurposing and combination therapy approaches for CoV treatment.

Main Results:

Accelerated advancements in antiviral drug discovery have been observed.
The study identifies key areas for developing effective broad-spectrum treatments.

Conclusions:

The lack of broad-spectrum antivirals leaves public health systems vulnerable to novel CoV outbreaks.
Prioritizing the development of broad-spectrum antivirals is essential for future pandemic preparedness and mitigation.